An adverse drug response (ADR) is a negative or damaging reaction that occurs after taking a medication or medication combination under everyday circumstances and is thought to be caused by the medication. Usually, an ADR calls for stopping the medication or lowering the dose. An adverse reaction is any injury that happens to a patient while they are taking medication, regardless of whether the medication is thought to be the cause or not. Any impact medicine has that is not the intended therapeutic effect—whether positive, negative, or neutral—is considered a side-effect. Although the terms "side-effect" and "ADR" are sometimes used interchangeably, the former generally denotes a less negative, predictable impact that may not even necessitate stopping therapy (e.g., ankle edema with vasodilators.) When a medicine's dosage or plasma concentration exceeds the therapeutic range, whether purposefully or inadvertently, it can lead to undesirable consequences. These unfavourable effects are referred to as drug toxicity (drug overdose). Addiction or dependency, major physiological harm (such as damage to the kidneys, liver, or heart), psychological impairment (abnormal behaviour patterns, hallucinations, memory loss), or even death can result from the misuse of recreational or therapeutic substances.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia